Merck and Eisai report blended leads to Section 3 most cancers trial By Investing.com
RAHWAY, N.J. & NUTLEY, N.J. - Merck (NSE:) & Co., Inc. (NYSE:)…
Eisai will request reconsideration of preliminary determination for lecanemab in Australia By Investing.com
STOCKHOLM, Oct. 16, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA…
